Evidence map›Paper›PMID 38790254›Full record

ArticleGenes2024

In Silico CRISPR-Cas-Mediated Base Editing Strategies for Early-Onset, Severe Cone-Rod Retinal Degeneration in Three

Hoda Shamsnajafabadi, Maria Kaukonen, Julia-Sophia Bellingrath, Robert E MacLaren, Jasmina Cehajic-Kapetanovic

Abstract readCase Reports
In one paragraph

Article in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Metabolomic signatures suggest altered bile acid and energy metabolism in CRB1- retinopathies.Metabolomics : Official journal of the Metabolomic Society · 2026
    Article
  3. Novel Genotype-Phenotype Correlations inOphthalmology science · 2026
    Article
  4. The Specific Pathogenicity Pattern of the DifferentInternational journal of molecular sciences · 2025
    Article
  5. Expanding the Clinical Spectrum ofInternational journal of molecular sciences · 2025
    Article
  6. Robotising vitreoretinal surgeries.Eye (London, England) · 2025
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hoda ShamsnajafabadiNuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, Oxford University, Oxford OX3 9DU, UK.ORCID 0000-0002-7043-3835
Maria KaukonenNuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, Oxford University, Oxford OX3 9DU, UK.
Julia-Sophia BellingrathNuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, Oxford University, Oxford OX3 9DU, UK.
Robert E MacLarenNuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, Oxford University, Oxford OX3 9DU, UK.
Jasmina Cehajic-KapetanovicNuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, Oxford University, Oxford OX3 9DU, UK.ORCID 0000-0002-9956-6412

Funding

Medical Research Council MR/V029762/1UKRI MRC, NIHR Oxford BRC to JCK, University of Oxford. UKRI MRC, NIHR Oxford BRC to JCK, University of Oxford.
6 · The paper itself

Abstract

Pathogenic variants in the

Indexed as

CRISPR-Cas SystemsEye ProteinsGene EditingMembrane ProteinsNerve Tissue ProteinsAdultComputer SimulationCone-Rod DystrophiesFemaleGenetic TherapyHumansMaleRetrospective StudiesYoung AdultCRB1 protein, humanEye ProteinsMembrane ProteinsNerve Tissue Proteinscone–rod retinal degenerationCRISPR-Cas mediated base editingCrumbs homolog 1 (CRB1)Müller glial cell degeneration

Identifiers

PMID38790254
PMCPMC11121323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.